REGN

695.42

0.03% 0.24

Handel nachbörslich: 695.42

Regeneron Pharmaceuticals Inc (REGN)

Überblick Nachrichten Preisverlauf Optionskette Financials Warum fällt REGN? Forum Prognose

Schlusskurs vom Vortag:

$695.18

Offen:

$699.38

24-Stunden-Volumen:

1.01M

Relative Volume:

1.05

Marktkapitalisierung:

$72.91B

Einnahmen:

$14.92B

Nettoeinkommen (Verlust:

$4.42B

KGV:

16.94

EPS:

41.0422

Netto-Cashflow:

$3.79B

1W Leistung:

+6.79%

1M Leistung:

+10.07%

6M Leistung:

-7.21%

1J Leistung:

+24.59%

1-Tages-Spanne:

$691.00

$702.60

1-Wochen-Bereich:

$637.80

$702.60

52-Wochen-Spanne:

$541.00

$821.11

Regeneron Pharmaceuticals Inc Stock (REGN) Company Profile

Firmenname

Regeneron Pharmaceuticals Inc

Sektor

Healthcare (1072)

Branche

Biotechnology (602)

Telefon

(914) 847-7000

Adresse

777 OLD SAW MILL RIVER ROAD, TARRYTOWN, NY

Mitarbeiter

15,410

Twitter

@regeneron

Nächster Verdiensttermin

2026-07-30

Neueste SEC-Einreichungen

REGN's Discussions on Twitter

Compare REGN vs VRTX, ARGX, RVMD, ALNY

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
REGN Regeneron Pharmaceuticals Inc	695.42	69.95B	14.92B	4.42B	3.79B	41.04
VRTX Vertex Pharmaceuticals Inc	483.33	121.57B	12.34B	4.34B	3.71B	16.87
ARGX Argen X Se Adr	882.56	55.61B	4.16B	1.29B	734.26M	19.58
RVMD Revolution Medicines Inc	180.76	39.98B	742.00K	-1.37B	-1.07B	-7.0731
ALNY Alnylam Pharmaceuticals Inc	286.62	37.17B	4.29B	577.22M	641.34M	4.2086

Regeneron Pharmaceuticals Inc Stock (REGN) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2026-03-31	Fortgesetzt	Piper Sandler	Overweight
2026-03-06	Eingeleitet	Barclays	Overweight
2026-01-07	Hochstufung	BofA Securities	Underperform → Buy
2025-12-03	Herabstufung	Morgan Stanley	Overweight → Equal-Weight
2025-11-24	Eingeleitet	HSBC Securities	Buy
2025-11-24	Fortgesetzt	Truist	Buy
2025-11-13	Eingeleitet	Scotiabank	Sector Perform
2025-08-14	Eingeleitet	Rothschild & Co Redburn	Buy
2025-06-30	Herabstufung	Argus	Buy → Hold
2025-05-30	Herabstufung	RBC Capital Mkts	Outperform → Sector Perform
2025-05-30	Herabstufung	Wells Fargo	Overweight → Equal Weight
2025-05-14	Hochstufung	Citigroup	Neutral → Buy
2025-04-22	Fortgesetzt	Cantor Fitzgerald	Overweight
2025-02-05	Hochstufung	Leerink Partners	Market Perform → Outperform
2025-01-16	Herabstufung	UBS	Buy → Neutral
2024-12-10	Fortgesetzt	BofA Securities	Underperform
2024-11-15	Eingeleitet	Wolfe Research	Outperform
2024-11-14	Eingeleitet	Citigroup	Neutral
2024-09-24	Herabstufung	Leerink Partners	Outperform → Market Perform
2024-03-12	Eingeleitet	Bernstein	Outperform
2024-01-12	Hochstufung	RBC Capital Mkts	Sector Perform → Outperform
2023-11-09	Eingeleitet	Deutsche Bank	Hold
2023-11-03	Hochstufung	Raymond James	Mkt Perform → Outperform
2023-08-21	Hochstufung	Canaccord Genuity	Hold → Buy
2023-08-21	Bestätigt	Oppenheimer	Perform
2023-06-28	Herabstufung	Canaccord Genuity	Buy → Hold
2023-03-27	Hochstufung	SVB Securities	Market Perform → Outperform
2023-03-24	Hochstufung	Jefferies	Hold → Buy
2023-03-23	Hochstufung	Raymond James	Underperform → Mkt Perform
2023-01-30	Hochstufung	Cowen	Market Perform → Outperform
2023-01-20	Hochstufung	JP Morgan	Neutral → Overweight
2022-10-26	Herabstufung	Raymond James	Mkt Perform → Underperform
2022-10-17	Herabstufung	Evercore ISI	Outperform → In-line
2022-09-09	Hochstufung	Jefferies	Underperform → Hold
2022-09-09	Hochstufung	Morgan Stanley	Equal-Weight → Overweight
2022-07-25	Herabstufung	SVB Leerink	Outperform → Mkt Perform
2022-07-13	Eingeleitet	Cantor Fitzgerald	Neutral
2022-06-06	Eingeleitet	Jefferies	Underperform
2022-05-23	Eingeleitet	SVB Leerink	Outperform
2022-01-05	Herabstufung	BofA Securities	Neutral → Underperform
2022-01-03	Hochstufung	Bernstein	Mkt Perform → Outperform
2021-12-15	Herabstufung	Bernstein	Outperform → Mkt Perform
2021-12-09	Fortgesetzt	Wells Fargo	Overweight
2021-12-07	Fortgesetzt	Cowen	Market Perform
2021-12-06	Eingeleitet	Goldman	Buy
2021-11-19	Fortgesetzt	BMO Capital Markets	Outperform
2021-11-05	Herabstufung	The Benchmark Company	Buy → Hold
2021-06-29	Eingeleitet	H.C. Wainwright	Buy
2021-01-25	Hochstufung	BMO Capital Markets	Market Perform → Outperform
2021-01-13	Hochstufung	The Benchmark Company	Hold → Buy
2021-01-08	Hochstufung	Citigroup	Neutral → Buy
2020-10-05	Hochstufung	Cantor Fitzgerald	Neutral → Overweight
2020-08-20	Herabstufung	The Benchmark Company	Buy → Hold
2020-07-09	Hochstufung	SunTrust	Hold → Buy
2020-05-26	Hochstufung	Wells Fargo	Equal Weight → Overweight
2020-04-28	Herabstufung	Citigroup	Buy → Neutral
2020-04-17	Hochstufung	The Benchmark Company	Hold → Buy
2020-04-08	Eingeleitet	The Benchmark Company	Hold
2020-03-31	Eingeleitet	Wolfe Research	Peer Perform
2020-02-27	Eingeleitet	Barclays	Overweight
2020-02-26	Hochstufung	Canaccord Genuity	Hold → Buy
2020-02-26	Herabstufung	Robert W. Baird	Outperform → Neutral
2020-02-25	Hochstufung	Jefferies	Hold → Buy
2020-02-11	Hochstufung	Argus	Hold → Buy
2019-12-24	Eingeleitet	Raymond James	Mkt Perform
2019-12-16	Herabstufung	Evercore ISI	Outperform → In-line
2019-12-13	Hochstufung	Credit Suisse	Neutral → Outperform
2019-11-12	Eingeleitet	SunTrust	Hold
2019-11-07	Hochstufung	Citigroup	Neutral → Buy
2019-10-17	Fortgesetzt	BofA/Merrill	Neutral
2019-09-23	Hochstufung	Guggenheim	Neutral → Buy

Alle ansehen

Regeneron Pharmaceuticals Inc Aktie (REGN) Neueste Nachrichten

Jul 28, 2026

REGN Shareholder Alert: September 14, 2026 Lead Plaintiff Deadline in Regeneron Pharmaceuticals, Inc. Securities Class ActionContact The Gross Law Firm - PR Newswire

Jul 28, 2026

Can These 5 Biotech Stocks Beat Wall Street's Q2 Estimates? - TradingView

Jul 28, 2026

REGN Class Reminder: Regeneron Investors are Reminded of the Upcoming September 14 Deadline in the Filed Securities Fraud Class Action to Recover Losses - PR Newswire

Jul 28, 2026

Jul 27, 2026

(REGN) Volatility Zones as Tactical Triggers - Stock Traders Daily

Jul 27, 2026

Regeneron Pharmaceuticals (NASDAQ: REGN) Investors Who Suffered Losses May Be Eligible to Participate in the Securities Class Action; Contact Robbins LLP for Information About Recovering Your Losses - PR Newswire

Jul 27, 2026

Regeneron Says Drug Approval Irrelevant In Antitrust Case - Law360

Jul 27, 2026

Regeneron on track to build in Saratoga - The Daily Gazette

Jul 27, 2026

Regeneron Pharmaceuticals (REGN) Q2 2026 Preview: EPS Est. $10.26, Reports July 30 - AlphaStreet

Jul 27, 2026

REGN DEADLINE: Levi & Korsinsky Reminds Regeneron - GlobeNewswire

Jul 27, 2026

Portnoy Law Firm Announces Class Action on Behalf of Regeneron Pharmaceuticals, Inc. Investors - GlobeNewswire

Jul 27, 2026

Portnoy Law Firm Announces Class Action on Behalf of Regeneron Pharmaceuticals, Inc. Investors - GlobeNewswire Inc.

Jul 27, 2026

Curious about Regeneron (REGN) Q2 Performance? Explore Wall Street Estimates for Key Metrics - Yahoo Finance

Jul 27, 2026

$REGN Lawsuit Notice: BFA Law Reminds Regeneron Investors - GlobeNewswire

Jul 27, 2026

14,700 Shares in Regeneron Pharmaceuticals, Inc. $REGN Acquired by Orbimed Advisors LLC - MarketBeat

Jul 27, 2026

3,883 Shares in Regeneron Pharmaceuticals, Inc. $REGN Purchased by Lombard Odier Asset Management Switzerland SA - MarketBeat

Jul 27, 2026

Renaissance Technologies LLC Has $51.61 Million Stock Holdings in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat

Jul 27, 2026